SPOTLIGHT -
Dr. Tarhini on Recent Practice-Changing Clinical Trials in Melanoma
Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses some recent practice-changing clinical trials in melanoma.
Read More
Dr. Tarhini Discusses Adjuvant Therapy for Melanoma
Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses adjuvant therapy for patients with melanoma.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
